AnaptysBio
ANAB
71 hedge funds and large institutions have $620M invested in AnaptysBio in 2017 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 31 increasing their positions, 10 reducing their positions, and 6 closing their positions.
317% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 6
210% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 10
89% more capital invested
Capital invested by funds: $328M → $620M (+$292M)
37% more funds holding
Funds holding: 52 → 71 (+19)
19.57% more ownership
Funds ownership: 67.61% → 87.17% (+20%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$59.1M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$18.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$15.7M |
| 4 |
BlackRock
New York
|
+$10.3M |
| 5 |
Millennium Management
New York
|
+$7.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$49.7M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$7.55M |
| 3 |
MWNA
Marshall Wace North America
New York
|
-$4.27M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$3.96M |
| 5 |
AG
Artal Group
Luxembourg
|
-$2.7M |
ANAB Hedge Fund Activity: Q3 2017 in Review
71 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q3 2017, worth a combined $620M — up 89% from $328M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ANAB positions and 6 closed out — a net gain of 19 holders — while 31 added to existing stakes and 10 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $59.1M. The largest seller was Novo Holdings A/S, cutting an estimated $49.7M.
- 71 institutional investors held AnaptysBio (ANAB) as of Q3 2017, up from 52 in Q2 2017.
- Funds reported $620M of AnaptysBio stock for Q3 2017, up 89% quarter-over-quarter.
- 25 funds opened new AnaptysBio positions in Q3 2017 and 6 closed out, a net change of +19 holders.
- The largest AnaptysBio buyer in Q3 2017 was Fidelity Investments, an estimated $59.1M added.
- The largest AnaptysBio seller in Q3 2017 was Novo Holdings A/S, an estimated $49.7M sold.
Based on aggregated 13F filings for Q3 2017.